9月8日，金斯瑞生物科技盘中上涨3.81%，报32.18港元/股，成交额7339.62万港元。
消息面上，公司此前公告拟将间接非全资附属公司蓬勃生物分拆并于联交所主板独立上市，联交所上市委员会已于8月14日确认公司可继续推进该计划。受分拆消息叠加获利回吐影响，公司股价此前连续回调，一度自高位回落逾12%。当前多家机构维持买入评级，小摩、中金、交银国际、华泰证券目标价区间为32至36港元，均高于近期低点，为股价提供估值支撑。此外，公司上半年AIDD相关业务同比翻倍增长，生命科学收入同比增长28.8%，基本面向好也为反弹提供基础。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.